BioPharma Dive 23. Feb. 2026 Novo’s next-gen obesity shot fails to match Lilly drug in head-to-head study
BioPharma Dive 19. Feb. 2026 Altesa, run by former Trump official, raises $75M for well-traveled lung drug
BioPharma Dive 19. Feb. 2026 FDA leaders say one pivotal trial, not two, should be ‘default’ for drug approvals
BioPharma Dive 18. Feb. 2026 FDA accepts BMS protein degrader for review; Disc rare disease drug rejected